173 related articles for article (PubMed ID: 14767530)
1. Suppression of prostate tumor cell growth in vivo by WT1, the Wilms' tumor suppressor gene.
Fraizer G; Leahy R; Priyadarshini S; Graham K; Delacerda J; Diaz M
Int J Oncol; 2004 Mar; 24(3):461-71. PubMed ID: 14767530
[TBL] [Abstract][Full Text] [Related]
2. Overexpression of bcl-2 protects prostate cancer cells from apoptosis in vitro and confers resistance to androgen depletion in vivo.
Raffo AJ; Perlman H; Chen MW; Day ML; Streitman JS; Buttyan R
Cancer Res; 1995 Oct; 55(19):4438-45. PubMed ID: 7671257
[TBL] [Abstract][Full Text] [Related]
3. Restoration of transforming growth factor beta signaling pathway in human prostate cancer cells suppresses tumorigenicity via induction of caspase-1-mediated apoptosis.
Guo Y; Kyprianou N
Cancer Res; 1999 Mar; 59(6):1366-71. PubMed ID: 10096572
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of caspases by cytokine response modifier A blocks androgen ablation-mediated prostate cancer cell death in vivo.
Srikanth S; Kraft AS
Cancer Res; 1998 Feb; 58(4):834-9. PubMed ID: 9485043
[TBL] [Abstract][Full Text] [Related]
5. Functional properties of WT1.
Haber DA; Englert C; Maheswaran S
Med Pediatr Oncol; 1996 Nov; 27(5):453-5. PubMed ID: 8827073
[TBL] [Abstract][Full Text] [Related]
6. Progression to androgen independence is delayed by adjuvant treatment with antisense Bcl-2 oligodeoxynucleotides after castration in the LNCaP prostate tumor model.
Gleave M; Tolcher A; Miyake H; Nelson C; Brown B; Beraldi E; Goldie J
Clin Cancer Res; 1999 Oct; 5(10):2891-8. PubMed ID: 10537358
[TBL] [Abstract][Full Text] [Related]
7. Regulation of the proto-oncogenes bcl-2 and c-myc by the Wilms' tumor suppressor gene WT1.
Hewitt SM; Hamada S; McDonnell TJ; Rauscher FJ; Saunders GF
Cancer Res; 1995 Nov; 55(22):5386-9. PubMed ID: 7585606
[TBL] [Abstract][Full Text] [Related]
8. The tumor suppressor gene WT1 inhibits ras-mediated transformation.
Luo XN; Reddy JC; Yeyati PL; Idris AH; Hosono S; Haber DA; Licht JD; Atweh GF
Oncogene; 1995 Aug; 11(4):743-50. PubMed ID: 7651738
[TBL] [Abstract][Full Text] [Related]
9. Proto-oncogene N-myc promoter is down regulated by the Wilms' tumor suppressor gene WT1.
Zhang X; Xing G; Saunders GF
Anticancer Res; 1999; 19(3A):1641-8. PubMed ID: 10470095
[TBL] [Abstract][Full Text] [Related]
10. Wilms' tumor 1 splice variants have opposite effects on the tumorigenicity of adenovirus-transformed baby-rat kidney cells.
Menke AL; Riteco N; van Ham RC; de Bruyne C; Rauscher FJ; van der Eb AJ; Jochemsen AG
Oncogene; 1996 Feb; 12(3):537-46. PubMed ID: 8637710
[TBL] [Abstract][Full Text] [Related]
11. Parathyroid hormone-related protein as a growth regulator of prostate carcinoma.
Dougherty KM; Blomme EA; Koh AJ; Henderson JE; Pienta KJ; Rosol TJ; McCauley LK
Cancer Res; 1999 Dec; 59(23):6015-22. PubMed ID: 10606251
[TBL] [Abstract][Full Text] [Related]
12. Wilms' tumor suppressor gene (WT1) as a target gene of SRY function in a mouse ES cell line transfected with SRY.
Toyooka Y; Tanaka SS; Hirota O; Tanaka S; Takagi N; Yamanouchi K; Tojo H; Tachi C
Int J Dev Biol; 1998 Nov; 42(8):1143-51. PubMed ID: 9879712
[TBL] [Abstract][Full Text] [Related]
13. WT1 expression alters tumorigenicity of the G401 kidney-derived cell line.
McMaster ML; Gessler M; Stanbridge EJ; Weissman BE
Cell Growth Differ; 1995 Dec; 6(12):1609-17. PubMed ID: 9019166
[TBL] [Abstract][Full Text] [Related]
14. Wilms' tumor 1-KTS isoforms induce p53-independent apoptosis that can be partially rescued by expression of the epidermal growth factor receptor or the insulin receptor.
Menke AL; Shvarts A; Riteco N; van Ham RC; van der Eb AJ; Jochemsen AG
Cancer Res; 1997 Apr; 57(7):1353-63. PubMed ID: 9102224
[TBL] [Abstract][Full Text] [Related]
15. Mutually exclusive expression patterns of Bcl-2 and Par-4 in human prostate tumors consistent with down-regulation of Bcl-2 by Par-4.
Qiu G; Ahmed M; Sells SF; Mohiuddin M; Weinstein MH; Rangnekar VM
Oncogene; 1999 Jan; 18(3):623-31. PubMed ID: 9989812
[TBL] [Abstract][Full Text] [Related]
16. Insulin-like growth factor binding protein-related protein 1 (IGFBP-rP1) is a potential tumor suppressor protein for prostate cancer.
Sprenger CC; Damon SE; Hwa V; Rosenfeld RG; Plymate SR
Cancer Res; 1999 May; 59(10):2370-5. PubMed ID: 10344746
[TBL] [Abstract][Full Text] [Related]
17. Analysis of WT1 target gene expression in stably transfected cell lines.
Thäte C; Englert C; Gessler M
Oncogene; 1998 Sep; 17(10):1287-94. PubMed ID: 9771972
[TBL] [Abstract][Full Text] [Related]
18. WT1 modulates apoptosis by transcriptionally upregulating the bcl-2 proto-oncogene.
Mayo MW; Wang CY; Drouin SS; Madrid LV; Marshall AF; Reed JC; Weissman BE; Baldwin AS
EMBO J; 1999 Jul; 18(14):3990-4003. PubMed ID: 10406804
[TBL] [Abstract][Full Text] [Related]
19. Androgens induce resistance to bcl-2-mediated apoptosis in LNCaP prostate cancer cells.
Berchem GJ; Bosseler M; Sugars LY; Voeller HJ; Zeitlin S; Gelmann EP
Cancer Res; 1995 Feb; 55(4):735-8. PubMed ID: 7850782
[TBL] [Abstract][Full Text] [Related]
20. Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer.
Taplin ME; Bubley GJ; Shuster TD; Frantz ME; Spooner AE; Ogata GK; Keer HN; Balk SP
N Engl J Med; 1995 May; 332(21):1393-8. PubMed ID: 7723794
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]